Libra Infusions (DHA:LIBRAINFU) Stock Based Compensation: BDT0.00 Mil (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:LIBRAINFU Libra Infusions Ltd DHA:LIBRAINFU
20 GF Score
Price BDT640.80
View Full Analysis

What is Libra Infusions Stock Based Compensation?

Libra Infusions DHA:LIBRAINFU -0.48% 20 Stock Based Compensation is BDT0.00 Mil as of . 20. GuruFocus rates DHA:LIBRAINFU with a GF Score™ of 20/100.

Libra Infusions's Stock Based Compensation for the six months ended in . 20 was BDT0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in . 20 was BDT0.00 Mil.

Libra Infusions Stock Based Compensation Related Terms

Libra Infusions Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Libra Infusions's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Libra Infusions Stock Based Compensation Chart

Libra Infusions Annual Data
Trend
Stock Based Compensation

Libra Infusions Semi-Annual Data
Stock Based Compensation
DHA:LIBRAINFU
20GF Score
Libra Infusions Ltd DHA:LIBRAINFU
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Libra Infusions Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Stock Based Compensation for the trailing twelve months (TTM) ended in . 20 was BDT0.00 Mil.

What does a Stock Based Compensation of BDT0.00 Mil mean?
Libra Infusions (DHA:LIBRAINFU) has a Stock Based Compensation of BDT0.00 Mil as of . 20. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Libra Infusions and its competitors.
Is Libra Infusions' Stock Based Compensation too high?
Libra Infusions' current Stock Based Compensation is BDT0.00 Mil. Overall, Libra Infusions has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Libra Infusions' Stock Based Compensation compare to SECI and LENSF?
Libra Infusions' Stock Based Compensation of BDT0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Libra Infusions and its competitors. Libra Infusions's current Stock Based Compensation is BDT0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Libra Infusions stock overvalued right now?
Libra Infusions (DHA:LIBRAINFU) has a current Stock Based Compensation of BDT0.00 Mil. The current Stock Based Compensation is BDT0.00 Mil. Libra Infusions' overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Libra Infusions (DHA:LIBRAINFU), the current Stock Based Compensation is BDT0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Libra Infusions Business Description

Address I/7, Mirpur Industrial Estate, Rupnagar, Section-2, Dhaka, BGD, 1216
Libra Infusions Ltd is engaged in manufacturing intravenous fluids. It provides products which are used for medical purposes involving surgical operations, loss of blood, weakness, and general hospitalization.
20GF Score

Get the complete analysis for DHA:LIBRAINFU

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT640.80
Price